Emcure's profit growth outpaced sales as margin recovered in Q1FY27
Revenue growth exceeded expense growth, while lower interest and tax rates lifted sequential profit; margin still trailed the healthcare peer median.
Filed 06 Aug 2026, 13:42 IST · Emcure Pharmaceuticals Ltd (EMCURE)
Key takeaways
- Consolidated net profit rose 36.17% year on year, ahead of revenue growth of 22.85%.
- Operating margin improved by 0.80 percentage points year on year to 20.64% as expenses grew slower than revenue.
- Q1FY27 margin remained 1.48 percentage points below the 22.12% median for 43 healthcare peers.
Price around the results
Profit growth ran ahead of revenue
On a consolidated basis, revenue grew 22.85% year on year and operating profit rose 27.77%, indicating some operating leverage. Net profit increased 36.17% to Rs 292.49 cr, helped by a 35.35% rise in pre-tax profit and a lower tax rate year on year. EPS rose 41.94% to Rs 15.50.
Lower costs and financing charges supported the margin
Expenses grew 21.63% year on year against 22.85% revenue growth, lifting operating margin by 0.80 percentage points; sequentially, the margin expanded 1.22 percentage points as revenue grew 4.48% and expenses 2.90%. Interest rose 17.91% year on year but fell 32.03% sequentially, while the tax rate declined 2.89 percentage points sequentially to support the 20.00% rise in net profit. Other income contributed only 0.53% of pre-tax profit, so reported earnings were not materially dependent on it.
Margin recovered from Q4 but remains below peers
Operating margin had declined from 20.95% in Q2FY26 to 20.85% in Q3FY26 and 19.42% in Q4FY26, before recovering to 20.64% in Q1FY27. The quarter's margin was 1.48 percentage points below the 22.12% median of 43 healthcare companies that had reported, placing Emcure 19th from the bottom on this measure.
Management linked expansion to the longer-term plan
Management said it expects continued full-year growth as its expanded team and portfolio gain traction, and said recent leadership changes are intended to support its five-year plan. The company said Gennova is now wholly owned and will remain its base for biologics and biosimilars. Management also reported entry into three new territories and more than 15 product approvals across Asia, Africa and LATAM in Q1FY27, while Canadian growth came from market-share gains and international performance was supported by the orderbook.
Past result-day moves have been mixed
After its eight recent results, the stock rose three times and fell five times, with a median absolute move of 3.19%. The recent sequence included moves of -1.82%, +1.91%, -3.99%, -1.52%, +9.99% and -5.64%, showing that the response has varied widely rather than following a consistent direction.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 | Q4FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹2,580 cr | ₹2,470 cr | +4.48% | +22.85% |
| Other income | ₹2 cr | ₹14 cr | -85.51% | +935.00% |
| Expenses | ₹2,048 cr | ₹1,990 cr | +2.90% | +21.63% |
| Operating profit | ₹533 cr | ₹480 cr | +11.04% | +27.77% |
| Operating margin (%) | 20.64% | 19.42% | — | — |
| Interest | ₹32 cr | ₹46 cr | -32.03% | +17.91% |
| Depreciation | ₹110 cr | ₹106 cr | +3.04% | +10.09% |
| Profit before tax | ₹394 cr | ₹341 cr | +15.34% | +35.35% |
| Tax | ₹101 cr | ₹97 cr | +3.68% | +32.99% |
| Net profit | ₹292 cr | ₹244 cr | +20.00% | +36.17% |
| EPS (₹) | ₹15.50 | ₹12.84 | +20.72% | +41.94% |
Operating margin of 20.64% compares with a Healthcare sector median of 22.12% across 43 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Guidance & outlook
- Emcure expects continued growth over the full year as its strengthened team and portfolio gain traction.
- The company says its leadership steps are intended to support delivery of its five-year plan.
Expansion
- Gennova Biopharmaceuticals is now a wholly-owned subsidiary of Emcure.
- Emcure expanded into three new territories and had more than 15 products approved across Asia, Africa and LATAM in Q1 FY27.
New orders
- Strong orderbook led performance in Emcure's international business.
New initiatives
- Samit Mehta was appointed COO with broader oversight of R&D, operations and licensing activities.
- Gennova will continue to anchor Emcure's biologics and biosimilars capabilities and complement its R&D and pipeline priorities.
Competition
- Emcure reported healthy Canadian growth through market share gains, balanced between Quebec and the rest of Canada.
What to watch
- Whether operating margin holds above 20.64% after the 1.22-percentage-point sequential recovery.
- Whether revenue growth stays ahead of expense growth, following +22.85% and +21.63% year-on-year growth respectively.
- Updates on the three new territories and the more than 15 products approved across Asia, Africa and LATAM.